Follow The Filings

IART Integra Lifesciences Holdings

Health Care, filed as INTEGRA LIFESCIENCES HLDGS (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 exit

In 2026 Q2 Lee Ainslie sold out of Integra Lifesciences.

Who owns IART

Sorted by value, long equity only, as of 2026 Q2.

History
Lee Ainslie, Maverick Capital exited 2026 Q2 Last 2026 Q1 0.01% Exit −0.01% 72,108 $679K History

0 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by IART's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IART insider trades
  • $102K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Jeffrey A Graves Director
    Buy
    $102K 9,000 shares at $11.35 +28% to stake
    Traded Nov 5, 2025 Filed Nov 6, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 17 share withholdings for taxes, 4 option exercises, and 2 stock grants.

Congress

1 member of Congress traded IART in the last three years: 0 buys and 2 sales.

All Congress trades
  1. Josh Gottheimer D-NJ-5Joint Partial sale $1K–$15K Jun 18, 2024 filed Jul 9, 2024
  2. Josh Gottheimer D-NJ-5Joint Partial sale $1K–$15K Apr 5, 2024 filed May 15, 2024

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
8-K 1.01,1.02,2.03,7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
DEFA14A Filing Doc
10-Q Filing Doc
8-K 1.01 Filing Doc
DEF 14A Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.54B $1.61B $1.64B
Gross profit * $884.74M $882.06M $831.62M
Gross margin * 57.4% 54.8% 50.9%
Net income $67.74M -$6.94M -$516.47M
Net margin * 4.4% -0.4% -31.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.06B $1.08B $1.16B
Total non-current assets * $2.72B $2.96B $2.44B
Total assets $3.78B $4.04B $3.6B
Total current liabilities $306.98M $922.13M $455.98M
Total non-current liabilities * $1.89B $1.57B $2.1B
Total equity $1.59B $1.55B $1.04B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $139.96M $129.38M $50.38M
Cash from investing -$94.18M -$390.81M -$108.06M
Cash from financing -$229.92M $237.86M $28.34M
Net change in cash -$180.26M -$30.03M -$11.33M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.